Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
nab-Paclitaxel vs Paclitaxel as Neoadjuvant Therapy in Triple-negative Breast Cancer
NCT04137653Phase 3Recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Jul 2021
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of paclitaxel in triple-negative breast cancer (TNBC), sponsored by Shengjing Hospital of China Medical University. Started Jul 2021; status: recruiting.
02
Drugs
paclitaxel
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04137653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04137653.